Latest From Biotech Now

Congress Passes Omnibus Spending Agreement

Jim Greenwood

This week, BIO President and CEO Jim Greenwood praised the Congress for passing the fundingbill for fiscal 2014, which would, among other things, allow the Food and Drug Administration (FDA) to access $85 million in user fees sequestered in 2013. In addition, BIO supports the agreement’s overall funding for: FDA, NIH, the biodefense enterprise; and improved program oversight of the important 340B program.  BIO also strongly supports the language in the bill providing the Department Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Bioscience’s Bright Spots

2014_BIO

According to Business Xpansion Journal, biotech is still big business and partnerships lead to profit. And BIO agrees. “In the past several years, it has become more important than ever for those in our industry to form partnerships and collaborations,” says Fritz Bittenbender, executive vice president, external affairs, BIO. “Big pharma, small biotechs, universities, investors, patient groups, the NIH – everyone is recognizing that success is only achieved by working with others. One place we’ve seen this Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

GMO Opposition Creates Uncertainty for Farmers!

Cathleen_Enright copy

Dr. Cathleen Enright, BIO’s Executive Vice President for Food and Agriculture, recently presented at the American Farm Bureau Federation’s 2014 Annual Convention in San Antonio. On Sunday, January 13th, Dr. Enright briefed the group on issues and challenges confronting the agricultural biotechnology sector at her workshop titled, “Ensuring Our Access to Biotechnology.” Christopher Doering of the Des Moines Register wrote a wonderful piece capturing the essence of her talk. In his blog titled, Opposition to Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , ,

Couldn’t Make it to San Francisco This Week?

20070112

Me neither, so here is what I am reading for updates about the 32nd Annual JPMorgan Healthcare Conference. Before arriving, hopefully you read the survival guide put forth by the InVivo blog team. In it, Chris Morrison and team outlined a few helpful talking points to help you when running in to industry colleagues. Likewise, Luke Timmerman, from Xconomy, has all the industry news you need to know heading in to the event, perhaps most importantly; who he thinks should Read More >

Business and Investments, Events  |  1 Comment  |  Email This Post
Tags: , , , , ,

BIO White Paper Highlights Key Industry Legislation and its Impact on the Industry

Emerging-Companies115x76

Innovative biotech companies at all stages of the development process are working toward next generation technologies to heal, fuel, and feed the world. In an effort to highlight promising policy legislation and its impact on the biotech sector, BIO has authored the following white paper: The Future Policy Landscape for Emerging Biotechnology Companies. Many research-intensive companies rely on private investment to support their groundbreaking R&D. Therefore, favorable legislation such as the JOBS Act is essential Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,